By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Northwest Biotherapeutics, Inc. 

21720 23rd Drive SE, Suite 100

Bothell  Washington  98021  U.S.A.
Phone: 425-608-3000-or-877-606-9246-Toll-Free Fax: 425-608-3026


SEARCH JOBS


Industry
Services


Collaborations

Cytogen Corporation  Development of ex vivo prostate cancer immunotherapy





Company News
Northwest Biotherapeutics (NWBO) Reports $35M In Financing 11/20/2014 5:58:07 AM
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Hospital Exemption Program Now Under Way In Germany 10/14/2014 12:50:20 PM
Northwest Biotherapeutics (NWBO) Secures $11.5 Million Financing 10/7/2014 7:11:59 AM
Experimental Northwest Biotherapeutics (NWBO) Drug Gets First Slot Under UK Early Access Scheme 9/16/2014 6:00:01 AM
Northwest Biotherapeutics (NWBO) CEO To Present At SMI's 3rd Annual Cancer Vaccines Conference In London 9/15/2014 9:30:39 AM
Northwest Biotherapeutics (NWBO) To Present Updates At Rodman & Renshaw 16th Annual Global Investment Conference 9/8/2014 9:00:16 AM
Northwest Biotherapeutics (NWBO) Completes The Closing Of Its $17.5 Million Convertible Note Offering 8/19/2014 12:57:39 PM
Northwest Biotherapeutics (NWBO) Announces Pricing Of $17.5 Million Offering Of Convertible Notes 8/14/2014 10:47:33 AM
Northwest Biotherapeutics (NWBO) Corrects Ongoing False Claims, Phase 3 Dcvax®-L Trial Is Alive And Well 8/13/2014 7:47:40 AM
Northwest Biotherapeutics (NWBO) Obtains Approvals For Enhancements Of Phase 3 Trial Of Dcvax®-L For Gbm Brain Cancer 8/11/2014 7:46:45 AM
12345678910...
//-->